Back to top
more

Quanterix (QTRX)

(Real Time Quote from BATS)

$16.03 USD

16.03
134,121

+0.47 (3.02%)

Updated Apr 29, 2024 01:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (142 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Quanterix (QTRX) AD Offering Gets FDA's Breakthrough Device Tag

by Zacks Equity Research

Quanterix's (QTRX) blood-based biomarker test offers a non-invasive alternative, potentially revolutionizing how AD is diagnosed and managed.

Quanterix Corporation (QTRX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Quanterix Corporation (QTRX) delivered earnings and revenue surprises of -17.86% and 13.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Quanterix (QTRX) Expands in Alzheimer's Testing With Alliances

by Zacks Equity Research

Quanterix's (QTRX) blood-based biomarker testing offers a superior alternative, aligning with the recommendations of the NIA-AA criteria for AD diagnosis.

Here's Why Quanterix Corporation (QTRX) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Quanterix Corporation (QTRX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Does Quanterix Corporation (QTRX) Have the Potential to Rally 33.74% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Quanterix Corporation (QTRX) points to a 33.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 54.88% Upside in Quanterix Corporation (QTRX): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for Quanterix Corporation (QTRX) points to a 54.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Analysts Estimate National Vision (EYE) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Teleflex (TFX) Advances Urology Portfolio With New Buyout

by Zacks Equity Research

Teleflex's (TFX) recent buyout is in line with its strategy of acquiring assets that accelerate the rate of expansion.

Here's Why You Should Hold on to Penumbra (PEN) Stock for Now

by Zacks Equity Research

Investors are optimistic about Penumbra (PEN), driven by strong vascular and neuro businesses.

Here's Why Investors Should Buy Bruker (BRKR) Stock Now

by Zacks Equity Research

The strong prospects of the BSI BioSpin and CALID group are likely to bode well for Bruker (BRKR) stock.

Haemonetics (HAE) Announces Agreement to Acquire OpSens

by Zacks Equity Research

Haemonetics' (HAE) acquisition of OpSens will expand its leadership in the interventional cardiology market.

Here's Why You Should Invest in Boston Scientific (BSX) Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific (BSX) on consistent growth and upbeat guidance.

Alcon (ALC) Expands Optical Care Line With Latest Launch

by Zacks Equity Research

Alcon's (ALC) new TOTAL30 Multifocal lens outwits digital device dryness by delivering nearly 100% water at the lens's surface via a patented Water Gradient Technology.

Here's Why You Should Retain Exact Sciences (EXAS) Stock Now

by Zacks Equity Research

Investors remain optimistic about Exact Sciences (EXAS) due to its strategic prioritization and positive solvency.

Thermo Fisher's (TMO) Strong End Markets and New Buyouts Aid

by Zacks Equity Research

Thermo Fisher (TMO) is registering strong growth in the electron microscopy and chromatography and mass spectrometry businesses in the academic and government end market.

Hyperfine (HYPR) Progresses in MRI Space With Latest FDA Nod

by Zacks Equity Research

Hyperfine's (HYPR) updated Swoop software is expected to make brain imaging more accessible and clinically relevant.

Here's Why You Should Retain Charles River (CRL) Stock Now

by Zacks Equity Research

Investors are optimistic about Charles River (CRL) on robust RMS segment growth and upbeat guidance.

ResMed (RMD) Gains From Strong Device Sales Amid Macro Woes

by Zacks Equity Research

ResMed's (RMD) respiratory care business continues to drive growth and the adoption of bilevel and other non-invasive ventilator solutions worldwide.

enVVeno (NVNO) Plans to Expedite enVVe Development for CVI

by Zacks Equity Research

enVVeno (NVNO) notes that its capital position is now strong enough to begin the enVVe pivotal study.

Here's Why You Should Retain Teleflex (TFX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Teleflex (TFX), led by growth in Vascular, Interventional and Surgical businesses.

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

by Zacks Equity Research

Investors remain optimistic about Tandem Diabetes (TNDM), backed by strategic developments and innovative new launches.

Santanu Roy headshot

Beat the Market the Zacks Way: UnitedHealth, Novo Nordisk, Check Point Software in Focus

by Santanu Roy

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Quest Diagnostics (DGX) to Boost Lab Services With New Pact

by Zacks Equity Research

Quest Diagnostics (DGX) latest deal will boost dialysis laboratory testing and reduce the laboratory costs of dialysis programs for ESRD patients.

Thermo Fisher (TMO) Expands Capabilities in St. Louis Facility

by Zacks Equity Research

Thermo Fisher (TMO) expands manufacturing capacity at the St. Louis site for Biologics treatment.

Here's Why You Should Buy Globus Medical (GMED) Stock Now

by Zacks Equity Research

Investors are optimistic about Globus Medical (GMED) on growing musculoskeletal devices demand and strong industry prospects.